The blood cancer drug has been given to a small number of sick U.S. patients and massive clinical trials are being launched to determine its efficacy, as well as that of Imbruvica.
EXCLUSIVE: AstraZeneca’s Calquence Shows Early Promise For COVID-19 Patients
